Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Most Cited Paper
in Cancer-related Molecular Pathways
18 Months Post-Publication
Class of 2026
“Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
HRS-4642 · KRAS G12D mutation · proteasome inhibition · combination therapy · KRAS mutation · anti-tumor efficacy
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459